Sovihep V Tablet is a combination antiviral medication primarily used in the treatment of chronic hepatitis C infection. It comprises Velpatasvir and Sofosbuvir, which together prevent the hepatitis C virus (HCV) from replicating.

Brand Name: Sovihep V

Composition: Sofosbuvir, Velpatasvir

Mechanism of Action:

By inhibiting the viral RNA polymerase, sofosbuvir, an NS5B polymerase inhibitor, stops the virus from replicating. Velpatasvir is an NS5A inhibitor that prevents the hepatitis C virus from replicating and assembling.

Uses:

Chronic Hepatitis C Infection

Dosage and Administration:

One tablet taken once a day, with or without food, is the usual dosage. The length of treatment varies from 12 to 24 weeks, depending on the virus's genotype and past treatment history.

Side Effects:

• Fatigue
• Headache
• Nausea
• Vomiting
• Fever
• Cough
• Insomnia
• Liver Function Abnormalities
• Allergic Reactions

Safety Advise:

Kidney  

Monitor kidney function regularly, as sovihep can cause nephrotoxicity. Kindly speak with your healthcare provider.

Liver  

Monitor liver function regularly, as sovihep can cause liver impairement. Kindly speak with your healthcare provider.

Pregnancy  

Sovihep should be used during pregnancy only if clearly needed, Kindly speak with your healthcare provider.

Breast Feeding  

Using sovihep while nursing is most likely dangerous. Kindly speak with your healthcare provider.

Alcohol  

Sovihep should not be taken with alcohol. Kindly speak with your healthcare provider.

Storage:

Store Sovihep Tablet at a temperature between 15°C and 30°C (59°F to 86°F). Keep the tablets in the original packaging to protect them from light and moisture. Keep out of reach of children.

References:

1.      Greig SL. Sofosbuvir/velpatasvir: a review in chronic hepatitis C. Drugs. 2016 Oct;76(16):1567-78.

2.    Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. New England Journal of Medicine. 2015 Dec 31;373(27):2608-17.

3.      Jackson WE, Everson GT. Sofosbuvir and velpatasvir for the treatment of hepatitis C. Expert review of gastroenterology & hepatology. 2017 Jun 3;11(6):501-5.

4.    Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, McNally J, Brainard DM, Han L, Doehle B, Mogalian E. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Annals of internal medicine. 2015 Dec 1;163(11):809-17.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details

Name: Zydus Life Sciences

Address: Zydus Corporate Park, Scheme No.63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, Sarkhej - Gandhinagar High, Ahmedabad, Gujarat, India-382481

Country of origin: India